Mitochondrial Redox Modulation in Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial Comparing Imeglimin vs. Metformin Monotherapy
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 176 participants.
Also called NCT07436182
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose basic science
- Phase
- Phase 4
- Enrolled
- 176 participants
- Sponsor
- Registry
-
NCT07436182
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Egypt
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07436182. Randomized; single masking; primary purpose basic science. Start 2026-03-01 (anticipated); primary completion 2026-06-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Mitochondrial Redox Modulation in Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial Comparing Imeglimin vs. Metformin Monotherapy
- Acronym
- MIRROR-DM
- Condition
- Mitochondria
- Condition
- Metformin
- Intervention (Drug)
- Imeglimin
- Intervention (Drug)
- Metformin 1000 mg Oral Tablet
- Lead sponsor
- Mansoura University
Record details
- Record id
cardio:ct-nct07436182- Content hash
aaa6a418c221dd8810d81c0a9ff07c7a94cbd0d4847a03e3df67fd969564c015